It's an older code sir, but it's still valid.
NASA Goddard Space Flight Center's Dr. Jennifer Wiseman explains the Hubble Space Telescope's view of the Pillars of Creation ...
BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, ...
BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's ...
Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial RECIST data with apparent stable disease lasting over 4 months ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage biotech company with a market capitalization of $11.27 million, announced Tuesday the completion of its Phase 1a clinical trial ...
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial RECIST data with apparent stable disease lasting over 4 months in 44% of patients (7 out of 16) ...
The MarketWatch News Department was not involved in the creation of this content. -- TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences -- Concurrent ...
TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...
BOSTON/SAN DIEGO - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company currently valued at approximately $10 million, announced today it has acquired Polynoma LLC, a privately-held ...